Here we looked to characterise whether FLT3-ITD mutated primary AML and AML cell lines, which accounts for approximately 20% of all AML14, responds to BTK inhibition by ibrutinib treatment. This evidence concerns the gene FLT3 and acute myeloid leukemia.